Valion Bio, Inc. has announced a significant investment agreement with 3i, LP, involving the sale of Series B Preferred Shares and warrants. This deal, valued at $700,000, is a strategic move for the company as it seeks to strengthen its financial position and support its growth in the pharmaceutical preparations sector.
The agreement, formalized in a letter dated November 6, 2026, allows 3i to purchase 700 Series B Preferred Shares and warrants to acquire 21,539 shares of common stock at an initial exercise price of $0.5182 per share. The funds raised will contribute to Valion Bio's ongoing efforts to expand its operations and product offerings.
Background
Valion Bio, Inc. is a Delaware-based company primarily engaged in the pharmaceutical preparations industry, as classified under SIC 2834. The company trades on the Nasdaq under the ticker symbol VBIO. Valion Bio has been active in the market, with recent filings indicating a series of transactions aimed at raising capital for growth and development.
What the Filing Says
According to the recent SEC filing (accession number 0001683168-26-008390), the company and 3i entered into a Securities Purchase Agreement, which allows for the purchase of up to 8,400 shares of Series B Non-Voting Convertible Preferred Stock and corresponding warrants. The filing states, "The Company issued and sold the Closing Series B Shares and the Closing Series B Warrants in reliance upon an exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933." This highlights the regulatory compliance aspect of the transaction.
Impact
This investment is likely to have a positive impact on Valion Bio's financial health, providing necessary capital to support its operations and strategic initiatives. The deal may also influence investor sentiment in the pharmaceutical preparations sector, as it demonstrates continued interest and confidence in Valion Bio's business model and growth potential.
What's Next
The company has committed to filing a registration statement with the SEC covering the maximum number of shares of common stock issuable upon conversion of the Closing Series B Shares and exercise of the Closing Series B Warrants. This registration is expected to occur within 30 days following the closing of the transaction.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










